Johnson & Johnson Management

Management criteria checks 2/4

Johnson & Johnson's CEO is Joaquin Duato, appointed in Jan 2022, has a tenure of 2.25 years. total yearly compensation is $28.40M, comprised of 5.6% salary and 94.4% bonuses, including company stock and options. directly owns 0.015% of the company’s shares, worth $53.07M. The average tenure of the management team and the board of directors is 4.4 years and 4.7 years respectively.

Key information

Joaquin Duato

Chief executive officer

US$28.4m

Total compensation

CEO salary percentage	5.6%
CEO tenure	2.3yrs
CEO ownership	0.02%
Management average tenure	4.4yrs
Board average tenure	4.7yrs

Recent management updates

Recent updates

Johnson & Johnson (NYSE:JNJ) Will Pay A Larger Dividend Than Last Year At $1.24

Apr 19

Johnson & Johnson: Buy This Bargain Before It's Gone

Apr 18

Johnson & Johnson Q1 Earnings Preview: Shockwave Could Be A Good Fit Despite Headwinds

Apr 11

Johnson & Johnson: Balance Growth Between MedTech And Medicine, Initiate With A 'Buy'

Jan 25

CEO Compensation Analysis

How has Joaquin Duato's remuneration changed compared to Johnson & Johnson's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	US$19b
Dec 31 2023	US$28m	US$2m	US$13b
Oct 01 2023	n/a	n/a	US$14b
Jul 02 2023	n/a	n/a	US$14b
Apr 02 2023	n/a	n/a	US$13b
Jan 01 2023	US$13m	US$1m	US$16b
Oct 02 2022	n/a	n/a	US$18b
Jul 03 2022	n/a	n/a	US$17b
Apr 03 2022	n/a	n/a	US$20b
Jan 02 2022	US$14m	US$1m	US$18b
Oct 03 2021	n/a	n/a	US$18b
Jul 04 2021	n/a	n/a	US$18b
Apr 04 2021	n/a	n/a	US$15b
Jan 03 2021	n/a	n/a	US$15b
Sep 27 2020	n/a	n/a	US$17b
Jun 28 2020	n/a	n/a	US$15b
Mar 29 2020	n/a	n/a	US$17b
Dec 29 2019	US$13m	US$970k	US$15b
Sep 29 2019	n/a	n/a	US$14b
Jun 30 2019	n/a	n/a	US$16b
Mar 31 2019	n/a	n/a	US$15b
Dec 30 2018	US$9m	US$934k	US$15b
Sep 30 2018	n/a	n/a	US$2b
Jul 01 2018	n/a	n/a	US$1b
Apr 01 2018	n/a	n/a	US$1b
Dec 31 2017	US$19m	US$897k	US$1b

Compensation vs Market: Joaquin's total compensation ($USD28.40M) is above average for companies of similar size in the US market ($USD13.41M).

Compensation vs Earnings: Joaquin's compensation has increased by more than 20% in the past year.

CEO

Joaquin Duato (60 yo)

2.3yrs

Tenure

US$28,397,240

Compensation

Mr. Joaquin Duato serves as Chief Executive Officer & Director of Johnson & Johnson since January 3, 2022 and serves as its Chairman since January 02, 2023. He served as Worldwide Chairman of Pharmaceutica...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Joaquin Duato	CEO & Chairman	2.3yrs	US$28.40m	0.015% $ 53.1m
Joseph Wolk	Executive VP & CFO	5.8yrs	US$13.91m	0.0029% $ 10.3m
Peter Fasolo	Executive VP & Chief Human Resources Officer	8yrs	US$7.50m	0.0046% $ 16.3m
Jennifer Taubert	Executive VP & Worldwide Chairman of Innovative Medicine	12.3yrs	US$11.00m	0.0064% $ 22.6m
John Reed	Executive Vice President of Innovative Medicine	less than a year	US$20.65m	0.000010% $ 35.1k
Robert Decker	Controller & Chief Accounting Officer	4.3yrs	no data	0.00082% $ 2.9m
James Swanson	Executive VP & Chief Information Officer	4.4yrs	no data	0.00060% $ 2.1m
Jessica Moore	Vice President of Investor Relations	2.4yrs	no data	no data
Dirk Brinckman	Chief Compliance Officer	no data	no data	no data
Elizabeth Forminard	Executive VP & General Counsel	1.5yrs	no data	0.00035% $ 1.2m
Guy Lebeau	Group Chairman of MD&D Business - EMEA	no data	no data	no data
William Hait	Executive VP	17.3yrs	no data	0.0016% $ 5.6m

4.4yrs

Average Tenure

59yo

Average Age

Experienced Management: JNJ's management team is considered experienced (4.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Joaquin Duato	CEO & Chairman	2.3yrs	US$28.40m	0.015% $ 53.1m
D. Davis	Independent Director	9.8yrs	US$350.00k	0% $ 0
Anne Mulcahy	Lead Independent Director	15.3yrs	US$410.00k	0.00034% $ 1.2m
Hubert Joly	Independent Director	4.3yrs	US$320.00k	0.00021% $ 737.5k
Marillyn Hewson	Independent Director	5yrs	US$360.00k	0.00012% $ 421.4k
Paula Johnson	Independent Director	1.2yrs	US$352.97k	0.000010% $ 35.1k
Mark McClellan	Independent Director	10.5yrs	US$320.00k	0% $ 0
Mary Beckerle	Independent Director	8.8yrs	US$360.00k	0% $ 0
Darius Adamczyk	Independent Director	2.2yrs	US$340.00k	0.000040% $ 140.5k
Jennifer Doudna	Independent Director	6yrs	US$320.00k	0% $ 0
Mark Weinberger	Independent Director	4.3yrs	US$340.00k	0% $ 0
Nadja West	Independent Director	3.3yrs	US$340.00k	0% $ 0

4.7yrs

Average Tenure

62.5yo

Average Age

Experienced Board: JNJ's board of directors are considered experienced (4.7 years average tenure).

Johnson & Johnson Management

Management criteria checks 2/4

Key information

Recent management updates

Insider recently sold US$1.4m worth of stock

Johnson & Johnson, Annual General Meeting, Apr 25, 2024

Insider notifies of intention to sell stock

Recent updates

Johnson & Johnson (NYSE:JNJ) Will Pay A Larger Dividend Than Last Year At $1.24

First quarter dividend increased to US$1.24

Johnson & Johnson: Buy This Bargain Before It's Gone

First quarter 2024 earnings: Revenues and EPS in line with analyst expectations

Johnson & Johnson Revises Earnings Guidance for the Full Year of 2024

Johnson & Johnson Announces Planned Presentation of New Non-Clinical Studies

Johnson & Johnson Q1 Earnings Preview: Shockwave Could Be A Good Fit Despite Headwinds

Johnson & Johnson Announces New Analysis of Data from the PionEER AF-PCI Clinical Trial Demonstrating XARELTO®? (rivaroxaban)

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Shockwave Medical, Inc. (NasdaqGS:SWAV) for $13 billion.

Johnson & Johnson to Showcase its Latest Innovations to Combat Cardiovascular Disease at ACC.24

With Lawsuit And Medtech Tailwinds - Johnson & Johnson May Be Back

Johnson & Johnson Reportedly Considers Deal for Shockwave Medical

Johnson & Johnson Announces U.S. Food and Drug Administration Approves Opsynvi as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension

Johnson & Johnson Announces U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Recommends Carvykti®? (Ciltacabtagene Autoleucel) for the Early Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Insider recently sold US$1.4m worth of stock

Johnson & Johnson, Annual General Meeting, Apr 25, 2024

Johnson & Johnson to Report Q2, 2024 Results on Jul 17, 2024

Johnson & Johnson Announces the First Data from FRONTIER 2, the Long-Term Extension of the Phase 2b FONTIER 1 Clinical Trial Evaluating JNJ-2113

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Ambrx Biopharma Inc. (NasdaqGS:AMAM) from a group of shareholders.

Johnson & Johnson: A Clean Bill Of Health

Johnson & Johnson Announces the U.S. Food and Drug Administration Approves the Supplemental Biologics License Application for TECVAYLI®?

Is There An Opportunity With Johnson & Johnson's (NYSE:JNJ) 43% Undervaluation?

Insider notifies of intention to sell stock

Johnson & Johnson: A High-Quality Dividend King Facing Furious Headwinds

Upcoming dividend of US$1.19 per share at 3.0% yield

Johnson & Johnson Announces Publication in the New England Journal of Medicine of the Phase 2b FRONTIER 1 Trial Results for JNJ-2113

Johnson & Johnson Reports Positive Topline Results for Nipocalimab from Phase 3 Pivotal Study in Generalized Myasthenia Gravis and Phase 2 Study in Sjögren's Disease

Johnson & Johnson Submits Supplemental Biologics License Application to U.S. FDA Seek Approval of DARZALEX FASPRO

Johnson & Johnson: Balance Growth Between MedTech And Medicine, Initiate With A 'Buy'

Johnson & Johnson Announces New Clinical and Real-World Evidence Data Will Be Featured in 18 Abstracts at This Year's ASCO GU Symposium

Full year 2023 earnings: EPS misses analyst expectations

Johnson & Johnson Provides Sales Guidance for the Full Year of 2024

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age